Myocardial infarction accelerates atherosclerosis
Partha Dutta,Gabriel Courties,Ying Wei,Florian Leuschner,Florian Leuschner,Rostic Gorbatov,Clinton S. Robbins,Yoshiko Iwamoto,Brian Thompson,Alicia L. Carlson,Timo Heidt,Maulik D. Majmudar,Maulik D. Majmudar,Felix Lasitschka,Martin Etzrodt,Peter Waterman,Michael T. Waring,Michael T. Waring,Adam T. Chicoine,Adam T. Chicoine,Anja M. van der Laan,Hans W.M. Niessen,Jan J. Piek,Barry B. Rubin,Jagdish Butany,James R. Stone,Hugo A. Katus,Sabina A. Murphy,David A. Morrow,Marc S. Sabatine,Claudio Vinegoni,Michael A. Moskowitz,Mikael J. Pittet,Peter Libby,Charles P. Lin,Filip K. Swirski,Ralph Weissleder,Matthias Nahrendorf +37 more
TL;DR: It is shown that the systemic response to ischaemic injury aggravates chronic atherosclerosis and provides a novel therapeutic opportunity to mitigate disease progression.
read more
Abstract: During progression of atherosclerosis, myeloid cells destabilize lipid-rich plaques in the arterial wall and cause their rupture, thus triggering myocardial infarction and stroke. Survivors of acute coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that the systemic response to ischaemic injury aggravates chronic atherosclerosis. After myocardial infarction or stroke, Apoe-/- mice developed larger atherosclerotic lesions with a more advanced morphology. This disease acceleration persisted over many weeks and was associated with markedly increased monocyte recruitment. Seeking the source of surplus monocytes in plaques, we found that myocardial infarction liberated haematopoietic stem and progenitor cells from bone marrow niches via sympathetic nervous system signalling. The progenitors then seeded the spleen, yielding a sustained boost in monocyte production. These observations provide new mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate disease progression.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
5mC modification patterns provide novel direction for early acute myocardial infarction detection and personalized therapy
Yiqun Guo,Huan Jiang,Jinlong Wang,Ping Li,Xiao R. Zeng,Tao Zhang,Jianyi Feng,RuQiong Nie,Yulong Liu,Xiao-bian Dong,Qingsong Hu +10 more
TL;DR: In this paper , the least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE) were employed to identify hub 5mC regulators in CAD to AMI progression, and 43 clinical samples were performed for expression validation.
Matthias Nahrendorf: Healing Insights.
TL;DR: Matthias Nahrendorf is pursuing a deeper understanding of the consequences of ischemic injury, especially regarding how monocytes/macrophages impact acute healing and scar development and how an imbalance in the process fuels prolonged inflammation and then heart failure.
1
The second myocardial infarction : A known but different experience
Ulrica Strömbäck
- 01 Jan 2018
TL;DR: The overall aim of this thesis was to explore the second myocardial infarction (MI) and describe experiences of the second heart attack from the perspectives of patients and personnel in clinical practice.
1
Inflammation: a denominating factor in coronary artery disease and venous bypass graft failure
K. Kupreishvili
- 16 Jan 2017
TL;DR: A putative relationship between CML and AMI is examined in patients with diabetes and in a rat model of AMI and in vitro in endothelial cells subjected to CML.
1
References
Inflammation in atherosclerosis
TL;DR: The new appreciation of the role of inflammation in atherosclerosis provides a mechanistic framework for understanding the clinical benefits of lipid-lowering therapies and unravelling the details of inflammatory pathways may eventually furnish new therapeutic targets.
9.9K
Inflammation in Atherosclerosis
TL;DR: The discovery of the immune basis of allograft arteriosclerosis demonstrated that inflammation per se can drive arterial hyperplasia, even in the absence of traditional risk factors.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P. Cannon,Eugene Braunwald,C. Mccabe,Daniel J. Rader,Jean L. Rouleau,Rene Belder,Steven V. Joyal,K. A. Hill,Marc A. Pfeffer,Allan M Skene +9 more
TL;DR: In patients with acute coronary syndromes, intensive lipid-lowering with atorvastatin (80mg) significantly reduces major cardiovascular events and death compared to moderate lipid-lowering with pravastatin (40mg), achieving lower LDL cholesterol levels and improved outcomes.
4.3K
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P. Cannon,Eugene Braunwald,Carolyn H. McCabe,Daniel J. Rader,Jean L. Rouleau,Rene Belder,Steven V. Joyal,Karen A. Hill,Marc A. Pfeffer,Allan M. Skene +9 more
TL;DR: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.
4.2K
Progress and challenges in translating the biology of atherosclerosis
TL;DR: Understanding how to combine experimental and clinical science will provide further insight into atherosclerosis and could lead to new clinical applications.
3.8K
Related Papers (5)
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more